Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7,